Tradestie Institutional Equity Comparison Engine

SYRE vs BMRN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMRN Overall Edge

BMRN Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin while SYRE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BMRN at 9.1x Forward P/E and 16.3% operating margin (+32.0% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BMRN
SYRE N/M vs BMRN 9.1x Fwd P/E
Growth & Margin Winner BMRN
Op Margin 0.0% vs 16.3% ยท YoY +0.0% vs +32.0%
Momentum & Technical Winner SYRE
1Y +341.7% vs +7.6% ยท 52W Pos 88% vs 42%
Options & Structure Winner SYRE
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (17th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
BMRN NASDAQ
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
1M Return +6.66%
1Y Return +7.56%
Forward P/E 9.1x
Unified AI Score
52.3 / 100 HOLD
Tech 56.0 Fund 61.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% BMRN +7.56% Spread: +334.18 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% BMRN TTM Op. Margin: 16.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs BMRN. Trailing 12-month operating profitability (SYRE 0.0% vs BMRN 16.3%) and valuation multiples (SYRE N/M vs BMRN 9.1x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (2) vs BMRN (8)
Institutional Metric SYRE BMRN Criterion Row Winner
Market Capitalization Scale $9.8B $11.0B Larger Scale BMRN
Trailing P/E Ratio Valuation N/M 8.8x Lower Multiple BMRN
Forward P/E Ratio Valuation N/M 9.1x Lower Multiple BMRN
Revenue Growth (YoY) Growth +0.0% +32.0% Higher Growth BMRN
Operating Margin (TTM) Profitability 0.0% 16.3% Higher Margin BMRN
Net Profit Margin Profitability 0.0% -0.5% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -35.0% -0.3% Higher ROE BMRN
52-Week Range Position Momentum 88% ($22โ€“$111) 42% ($49โ€“$71) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 0.28ฮฒ ยท 31% Vol Lower Realized Risk BMRN
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 52.3 / 100 (HOLD) Higher Composite BMRN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs BMRN Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BMRN CONSOLIDATION
67d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live BMRN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor BMRN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.